PrimaryCare Settingto Care Asthma
Main Article Content
Abstract
Chronic asthma is primarily distinguished by episodes of wheezing, coughing, and shortness of breath brought on by inflammation and hyperresponsiveness of the airways. It is one of the most prevalent chronic pulmonary illnesses in the US, affecting 20 million adults, or 8% of the adult population.
As a result, primary care offices commonly meet cases of asthma. Most asthmatics are anticipated to acquire good control, and the generalist manages asthma very successfully most of the time. The epidemiology, diagnosis, and chronic and acute therapy of asthma from a primary care perspective are all summarized in this article.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Villarroel MA, Blackwell DL. Percentage of adults aged 18–64 years with current asthma,* by State-National Health Interview Survey,(Dagger) 2014–2016. Atlanta (GA): Centers Disease Control 1600 Clifton Rd; 2018. 30333 USA.
II. CDC - Asthma - Most recent asthma data. 2018 Available at: https://www.cdc.gov/asthma/ most_recent_data.htm. Accessed September 14, 2018.
III. Mazurek JM. Prevalence of asthma, asthma attacks, and Emergency Department visits for asthma among working adults — national health interview survey, 2011 — 2016. MMWR Morb Mortal Wkly Rep 2018;67 10.15585/mmwr.mm6713a1.
IV. Winer RA, Qin X, Harrington T, et al. Asthma incidence among children and adults: findings from the behavioral risk factor surveillance system asthma call-back survey—United States, 2006–2008. J Asthma 2012;49(1):16–22. [PubMed: 22236442]
V. Huovinen E, Kaprio J, Koskenvuo M. Factors associated to lifestyle and risk of adult onset asthma. Respir Med 2003;97(3):273–80. [PubMed: 12645835]
VI. Guerra S, Sherrill DL, Martinez FD, et al. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109(3):419–25. [PubMed: 11897985]
VII. Jamrozik E, Knuiman MW, James A, et al. Risk factors for adult-onset asthma: a 14-year longitudinal study. Respirology 2009;14(6):814–21. [PubMed: 19703063]
VIII. Shen H, Hua W, Wang P, et al. A new phenotype of asthma: chest tightness as the sole presenting manifestation. Ann Allergy Asthma Immunol 2013;111(3):226–7. [PubMed: 23987204]
IX. Dixon AE. Rhinosinusitis and asthma: the missing link. Curr Opin Pulm Med 2009; 15(1):19–24. [PubMed: 19077701]
X. Vernon MK, Wiklund I, Bell JA, et al. What do we know about asthma triggers? a review of the literature. J Asthma 2012;49(10):991–8. [PubMed: 23574397]
XI. Henneberger PK, Redlich CA, Callahan DB, et al. An official American Thoracic Society statement: work-exacerbated asthma. Am J Respir Crit Care Med 2011;184(3):368–78. [PubMed: 21804122]
XII. Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med 2014;370(7):640–9. [PubMed: 24521110]
XIII. Work-related asthma: number of cases by classification and state, 2009–2012 Available at: https:// wwwn.cdc.gov/eworld/Data/Work- related_asthma_Number_of_cases_by_classification_and_state_20092012/924. Accessed September 14, 2018.
XIV. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948–68. [PubMed: 16264058]
XV. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary (vol 31, pg 143, 2008). Eur Respir J 2018;51(2):143–78Busse WW, Boushey HA, Camargo CA, et al. Expert panel report 3: guidelines for the diagnosis and management of asthma. Washington (DC): US Department of Health and Human Services, National Heart Lung and Blood Institute; 2007 p. 1–417.
XVI. Borak J, Lefkowitz RY. Bronchial hyperresponsiveness. Occup Med (Lond) 2016; 66(2):95–105. [PubMed: 26590957]
XVII. Cockcroft DW. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138(2, Supplement): 18S–24S. [PubMed: 20668014]
XVIII. Cockcroft DW, Murdock KY, Berscheid BA, et al. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol 1992;89(1, Part 1):23–30. [PubMed: 1730837]
XIX. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017;317(3):269–79. [PubMed: 28114551]
XX. Desai D, Brightling C. Cough due to asthma, cough-variant asthma and non-asthmatic eosinophilic bronchitis. Otolaryngol Clin North Am 2010;43(1):123–30. [PubMed: 20172262]
XXI. Corrao W, Braman S, Irwin R. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med 1979;300:633–7. [PubMed: 763286]
XXII. Niimi A Cough and asthma. Curr Respir Med Rev 2011;7(1):47–54. [PubMed: 22081767]
XXIII. McFadden ER, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330(19): 1362–7. [PubMed: 8152449]
XXIV. Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015;135(3):676–81.e1. [PubMed: 25282015]
XXV. Kenn K, Balkissoon R. Vocal cord dysfunction: what do we know? Eur Respir J 2011;37(1):194– 200. [PubMed: 21205712]
XXVI. Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117(3):549– 56. [PubMed: 16522452]
XXVII. Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14(4):902–7. [PubMed: 10573240]
XXVIII. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996;98(6):1016–8. [PubMed: 8977499]
XXIX. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004;126(6):1875–82. [PubMed: 15596687]
XXX. Osborne ML, Pedula KL, O’Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007;132(4):1151–61. [PubMed: 17573515]
XXXI. Petsky HL, Cates CJ, Kew KM, et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax 2018 10.1136/ thoraxjnl-2018-211540.
XXXII. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy 2017;10:47–56. [PubMed: 28331347]
XXXIII. GØtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008;(2). 10.1002/14651858.CD001187.pub3.
XXXIV. Platts-Mills TAE. Allergen avoidance in the treatment of asthma and rhinitis. N Engl J Med 2003;349(3):207–8. [PubMed: 12867602]
XXXV. Gibson PG, Henry R, Coughlan JJ. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003;(1). 10.1002/14651858.CD001496.
XXXVI. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev 2003;(3). 10.1002/14651858.CD003570.
XXXVII. Kim DK, Riley LE, Hunter P. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann Intern Med 2018;168(3):210–20. [PubMed: 29404596]
XXXVIII. Juel CT-B, Ali Z, Nilas L, et al. Asthma and obesity: does weight loss improve asthma control? a systematic review. J Asthma Allergy 2012;5:21–6. [PubMed: 22791994] Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. Chest 2006;129(3):573–80. [PubMed: 16537854]
XXXIX. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014;(1). 10.1002/14651858.CD003137.pub5.
XL. Ducharme F, Ni Chroinin M, Greenstone I, et al. The addition of long-acting beta2-agonists to inhaled steroids compared to higher doses of inhaled steroids alone as maintenance treatment for chronic asthma. Cochrane Database Syst Rev 2010;(4). 10.1002/14651858.CD005533.pub2.
XLI. Kew K, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016;(1). 10.1002/14651858.CD011721.pub2.
XLII. Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA 2018;319(14):1473–84. [PubMed: 29554174]
XLIII. Newman KB, Milne S, Hamilton C, et al. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002;121(4): 1036–41. [PubMed: 11948030]
XLIV. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004;43(6):349–60. [PubMed: 15086274]
XLV. Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest 2016;150(2):394–406. [PubMed: 27060726]
XLVI. Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 2013; 107(1):37–46. [PubMed: 23098685]
XLVII. CDC - Asthma - Using an asthma inhaler videos. 2018 Available at: https://www.cdc.gov/asthma/ inhaler_video/default.htm. Accessed September 15, 2018.
XLVIII. Asthma patient resources and videos. Available at: http://www.lung.org/lung-health-and-diseases/ lung-disease-lookup/asthma/patient-resources-and-videos/. Accessed September 15, 2018.
XLIX. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015 10.4187/respcare.03200.
L. Dima AL, Hernandez G, Cunillera O, et al. Asthma inhaler adherence determinants in adults: systematic review of observational data. Eur Respir J 2015; 45(4):994–1018. [PubMed: 25504997]
LI. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non- adherence in difficult to control asthma. Respir Med 2011;105(9): 1308–15. [PubMed: 21511454]
LII. Miller MR, Dickinson SA, Hitchings DJ. The accuracy of portable peak flow meters. Thorax 1992;47(11):904–9. [PubMed: 1465746]
LIII. McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018;378:902–10. [PubMed: 29504499]
LIV. Gibson PG, Powell H, Wilson A, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2002;(3). 10.1002/14651858.CD001117.
LV. Powell H, Gibson PG. Options for self-management education for adults with asthma. Cochrane Database Syst Rev 2002;(3). 10.1002/14651858.CD004107.
LVI. Asthma Action Plan | National Heart, Lung, and Blood Institute (NHLBI). Available at: https:// www.nhlbi.nih.gov/health-topics/all-publications-and-resources/asthma-action-plan. Accessed September 17, 2018.
LVII. CDC - Asthma - tools for asthma control. 2018 Available at: https://www.cdc.gov/asthma/ tools_for_control.htm. Accessed September 17, 2018.
LVIII. Create an asthma action plan | American Lung Association. Available at: https://www.lung.org/ lung-health-and-diseases/lung-disease-lookup/asthma/living-with-asthma/managing-asthma/ create-an-asthma-action-plan.html. Accessed September 17, 2018.
LIX. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2): 343–73. [PubMed: 24337046]
LX. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012;6:27–40. [PubMed: 22745565]
LXI. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–207. [PubMed: 25199059]
LXII. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3(5):355–66. [PubMed: 25736990]
LXIII. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, un-controlled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2128–41. [PubMed: 27609406]
LXIV. Lin SY, Azar A, Suarez-Cuervo C, et al. The role of immunotherapy in the treatment of asthma. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Available at: http:// www.ncbi.nlm.nih.gov/books/NBK513535/. Accessed September 16, 2018.
LXV. Dombret M-C, Alagha K, Boulet LP, et al. Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults. Eur Respir Rev 2014;23(134):510–8. [PubMed: 25445950]
LXVI. Chupp G, Laviolette M, Cohn L, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J 2017;50(2). 10.1183/13993003.00017-2017.
LXVII. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009;39(2):193–202. [PubMed: 19187331]
LXVIII. Cates CJ, Bara A, Crilly JA, et al. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2003;(2). 10.1002/14651858.CD000052.
LXIX. Strauss L, Hejal R, Galan G, et al. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med 1997;155(2):454–8. [PubMed: 9032178]
LXX. McFadden ER, Elsanadi N, Dixon L, et al. Protocol therapy for acute asthma: therapeutic benefits and cost savings. Am J Med 1995;99(6):651–61. [PubMed: 7503089]
LXXI. Krishnan JA, Davis SQ, Naureckas ET, et al. An umbrella review: corticosteroid therapy for adults with acute asthma. Am J Med 2009;122(11):977–91. [PubMed: 19854321]
LXXII. O’Byrne P, Pedersen S, Lamm CJ, et al. Severe Exacerbations and decline in lung function in asthma | American Journal of Respiratory and Critical Care Medicine. Am J Respir Crit Care Med 2008;179:19–24. [PubMed: 18990678]
LXXIII. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30(3):452–6. [PubMed: 17537763]
LXXIV. Wu AW, Young Y, Skinner EA, et al. Quality of care and outcomes of adults with asthma treated by specialists and generalists in managed care. Arch Intern Med 2001;161(21):2554–60. [PubMed: 11718586]
LXXV. Laforest L, Ganse EV, Devouassoux G, et al. Management of asthma in patients supervised by primary care physicians or by specialists. Eur Respir J 2006;27(1): 42–50. [PubMed: 16387934